Verona Pharma in partnering discussions for lead respiratory product
This article was originally published in Scrip
Executive Summary
Verona Pharma is in discussions with a number of pharmaceutical companies with regards to a potential licensing deal for its lead drug candidate RPL554. In line with its business strategy, the firm has been seeking a partner to advance the respiratory product following completion of a Phase I/II trial in November.